We used the UALCAN database to analyze the expression levels of FREM2 in pan-cancer and found that FREM2 was mainly highly expressed in COAD, glioblastoma multiforme (GBM), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC) (Figure 9A). Here, FREM2 is linked to glioblastoma.